MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Neuronetics Operating Income 2011-2026 | STIM
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Neuronetics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.1 M | -27.6 M | -22.3 M | -26.9 M | -19.8 M | -13.6 M | -9.34 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -9.34 M | -35.1 M | -22.1 M |
Quarterly Operating Income Neuronetics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.32 M | -8.06 M | -11 M | - | -7.73 M | -8.51 M | -6.86 M | - | -8.87 M | -7.35 M | -9.91 M | - | -7.45 M | -9.8 M | -10.1 M | - | -7.18 M | -6.56 M | -6.91 M | -2.66 M | -2.42 M | -6.86 M | -10.4 M | -6.94 M | -6.33 M | -6.61 M | -7.06 M | -5.66 M | -4.33 M | -5.24 M | -4.6 M | -4.23 M | -2.81 M | -2.58 M | -3.99 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.42 M | -11 M | -6.66 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 3.01 | -2.9 % | $ 97.7 K |  USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 23.56 | -2.04 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 33.99 | 0.65 % | $ 366 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.38 | -6.12 % | $ 1.75 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 39.01 | -0.38 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 218.94 | -0.24 % | $ 160 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 102.48 | 0.18 % | $ 19 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 26.01 | -0.88 % | $ 786 M | USA |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Guardant Health
GH
|
-444 M | $ 111.89 | 1.28 % | $ 13.7 B | USA |
 |
DexCom
DXCM
|
598 M | $ 73.26 | -1.0 % | $ 28.3 B | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 20.4 | -1.92 % | $ 1.1 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 109.94 | -1.94 % | $ 4.34 B | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 10.95 | 6.31 % | $ 311 M | Israel |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 65.82 | -1.3 % | $ 4.55 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 145.95 | -2.5 % | $ 23.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 230.03 | -2.31 % | $ 41.7 B | USA |
 |
NeoGenomics
NEO
|
-92.1 M | $ 11.85 | -4.44 % | $ 1.5 B | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 210.0 | -0.83 % | $ 10.8 B | USA |
 |
Medpace Holdings
MEDP
|
447 M | $ 583.39 | -1.63 % | $ 18.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 184.82 | 1.37 % | $ 20.5 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 8.94 | -7.45 % | $ 1.16 B | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 9.4 | -5.72 % | $ 557 M | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
-7.62 M | $ 24.39 | 0.54 % | $ 31.7 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 269.39 | -0.16 % | $ 22.6 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 179.07 | -3.67 % | $ 14.8 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.13 B | $ 674.78 | -0.29 % | $ 55.6 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 28.73 | -1.79 % | $ 20 B | Niderland |
 |
Agilent Technologies
A
|
1.35 B | $ 132.75 | -0.37 % | $ 40.4 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.39 | 0.21 % | $ 5.49 M | USA |